Health Care & Life Sciences » Pharmaceuticals | Sinco Pharmaceuticals Holdings Ltd.

Sinco Pharmaceuticals Holdings Ltd. | Income Statement

Fiscal year is January-December. All values HKD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
672
1,196
1,352
1,004
930
1,129
Cost of Goods Sold (COGS) incl. D&A
595
1,032
1,164
881
822
867
Gross Income
77
163
188
122
108
262
SG&A Expense
15
31
57
86
177
385
EBIT
59
123
131
36
98
123
Unusual Expense
-
-
-
-
77
29
Non Operating Income/Expense
-
5
1
16
16
130
Interest Expense
1
8
9
11
39
41
Pretax Income
64
118
107
30
225
322
Income Tax
10
17
21
8
10
10
Consolidated Net Income
54
101
86
21
214
332
Net Income
46
87
86
23
214
332
Net Income After Extraordinaries
46
87
86
23
214
332
Net Income Available to Common
46
87
86
23
214
332
EPS (Basic)
0.03
0.05
0.05
0.02
0.13
0.20
Basic Shares Outstanding
1,615
1,615
1,615
1,536
1,615
1,689
EPS (Diluted)
0.03
0.05
0.05
0.01
0.13
0.20
Diluted Shares Outstanding
1,615
1,615
1,615
1,536
1,615
1,689
EBITDA
61
125
144
48
80
111
Other Operating Expense
2
10
-
-
29
-
Non-Operating Interest Income
-
2
2
3
4
1
Minority Interest Expense
8
14
-
1
-
-

About Sinco Pharmaceuticals Holdings

View Profile
Address
E5-1805, Global Centre
Chengdu Sichuan 610041
China
Employees -
Website http://www.sinco-pharm.com
Updated 07/08/2019
Sinco Pharmaceuticals Holdings Ltd. engages in the marketing, promotion, and channel management services for pharmaceutical products and medical devices. It improves human plasma-based pharmaceutical, antibiotics, and other pharmaceuticals focused on therapeutic areas complementary to human plasma-based products. It offers human albumin solution, Axetine, Medocef, and Trifamox IBL.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.